Navigation Links
BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
Date:3/4/2008

BIRMINGHAM, Ala., March 4 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the fourth quarter and year ended December 31, 2007.

"In 2007, we gained greater clarity in terms of the progress made in each of our lead product programs, peramivir, forodesine HCl and BCX-4208," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "Each program is now either in mid-stage clinical testing or, in the case of forodesine HCl, a pivotal trial. Over the course of the year, we have assembled a strong management team to execute on our commitments and advance our product candidates in 2008."

Fourth Quarter 2007 Financial Results

The Company reported revenues of $28.2 million in the fourth quarter of 2007, compared to $2.1 million in the fourth quarter of 2006. The increase in revenues is due to revenue from the contract with the U.S. Department of Health and Human Services ("HHS") for the development of peramivir, a $7.0 million milestone payment received from Shionogi & Co., Ltd., and the continuing amortization of deferred revenue from our collaborative agreements.

The net loss for the quarter ended December 31, 2007 was $2.3 million, or $0.06 per share, compared to a net loss of $10.1 million, or $0.34 per share, for the quarter ended December 31, 2006.

Research and development ("R&D") expenses were $29.1 million in the fourth quarter of 2007, compared to $11.2 million in the fourth quarter of 2006. The increase in R&D expenses is primarily attributable to an increase in clinical trial related expenses, manufacturing costs for our lead product candidates and costs related to an increase in the personnel supporting the advanced development of our pro
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
2. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
5. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
6. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
8. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
9. Genetic Engineering & Biotechnology News reports on advances in miRNA
10. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
11. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 ReliantHeart, Inc., an ... Transonic, a supplier of precision transit-time flow measurement solutions, ... greatly improve the efficiency of the HeartAssist5® ... patients to experience greater mobility and peace of mind. ... miniature flow board, will draw 1/6th of the power ...
(Date:3/26/2015)... March 26, 2015 WriteResult, a premier ... researchers from Yale University’s School of Public Health and ... participants during a 4 month-long project. The goal of ... low income families with free access to fresh produce ... diet-related health concerns like high blood pressure, diabetes and ...
(Date:3/25/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... recent discussions with certain shareholders representing approximately 45% of ... dealing with certain matters including the appointment of auditors ... March 26, 2015 (the "Meeting") it intends to adjourn ... take place when the Meeting reconvenes. The Meeting will ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital ... Factual Stock Report coverage on Abattis Bioceuticals ... ATTBF; CSE: ATT): is a specialty biotechnology company ... cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, ... in North America . The ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... BERNARDSVILLE, N.J., March 16 Protocol Driven Healthcare ... its health risk assessment (HRA), the ConXus(R) ... low literacy and reduces processing costs of paper assessments. ... adult HRA, but joins PDHI,s suite of ConXus ...
... Provider, Offers Traceability Down to the Unit Level to Secure ... ... Southborough, MA (PRWEB) March 16, 2009 -- PHARMORX ... technology services provider, today announced the availability of its new ...
... Application Includes Data from a Comparative Trial in ... Inc. announced today that its supplemental New Drug ... Drug Administration (FDA) seeking market approval of Durezol(TM) ... uveitis has been accepted for review. Durezol, ...
Cached Biology Technology:PDHI Launches Short Form of Its ConXus Profile Health Assessment 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 3Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 2Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 3Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 4Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 5
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... Va. , March 12, 2015 IriTech, ... and a member of the Texas Instruments Design Network, ... Naidu has demonstrated its IriShield USB MK2120U device ... scanning facility for pension distribution. The ... assembled to be marketed in India ...
(Date:3/11/2015)... DUBLIN , Mar. 11, 2015 Research and ... addition of the "Access Control Market by Product, ... to 2020" report to their offering. , ... is expected to reach $10.4 billion by 2020, with ... control market report covers the products types such as ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... from the University of California at San Francisco (UCSF) ... dedicated to the brain that the controversy is over: ... dead. , The cerebral cortex is a sheet of ... that process particular aspects of sensation, movement and cognition. ...
... of genes has shed light on the role of gene ... in Proceedings of the National Academy of Sciences USA, was ... , Dr Robert Beiko, Professor Mark Ragan and Mr ... in an effort to map how genes are shared between ...
... used by the U.S. military to track vehicle convoys in ... little-known world of pygmy elephants in Borneo. , ... elephant's being captured and outfitted with a collar that can ... the first time, the public can track the movements of ...
Cached Biology News:MIT researcher presents new view of how the cortex forms 2Lateral thinking produces first map of gene transmission 2WWF peeks into mysterious life of Borneo's pygmy elephants 2
... System brings together two mature, well-understood ... capture surfaces. This combination produces a ... the detection of molecular binding events ... , Protein-specific capture molecules are immobilized ...
... polymers) are prepared by ... the enzyme, polynucleotide phosphorylase, ... the appropriate, ribonucleoside diphosphate ... exception of catalog number ...
... comprehensive experiment based analysis package designed with ... sophisticated and powerful functionality., Image acquisition interface ... for easy image capture. Sequential and ... Playback Saturation Warning ...
...
Biology Products: